Form 4: Halozyme CEO Exercises, Sells Shares Under 10b5-1 Plan

Halozyme Therapeutics' President and CEO, Helen Torley, exercised stock options and subsequently sold common stock in early September 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Helen Torley, President and CEO of Halozyme Therapeutics, Inc., executed a series of transactions on September 2, 3, and 4, 2025, under a Rule 10b5-1 trading plan adopted on March 21, 2025.
• On each of these three days, Torley exercised options to acquire 20,000 shares of common stock at an exercise price of $8.11 per share. These options were granted on February 3, 2016, and are set to expire in February 2026.
• Immediately following each option exercise, Torley sold 20,000 shares of common stock on the open market.
• On September 2, 2025, 20,000 shares were sold at weighted average prices ranging from $72.485 to $74.147.
• On September 3, 2025, 20,000 shares were sold at weighted average prices ranging from $74.22 to $74.632.
• On September 4, 2025, 20,000 shares were sold at weighted average prices ranging from $73.536 to $75.224.
• The net effect of the transactions on each day was zero change in her direct beneficial ownership of common stock, with her ownership remaining at 733,719 shares after all reported transactions on September 4, 2025.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of pre-planned insider transactions (option exercises and subsequent sales) under a Rule 10b5-1 plan. Such transactions are common for executives to manage personal finances and diversify holdings, and do not typically reflect a change in the company's fundamental outlook or performance. Therefore, it is considered neutral in its impact on the company's prospects.

Positives

• The executive realized significant value from long-held stock options, indicating the company's stock appreciation since the options were granted in 2016.
• Transactions were conducted under a Rule 10b5-1 trading plan, demonstrating a structured and pre-planned approach to insider stock sales, which is a positive for corporate governance.

Negatives

• No direct negative implications for the company's operations or financial health are indicated by these routine insider transactions.

Future Outlook

This Form 4 filing, detailing routine insider transactions, does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The options exercised and sales reported were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025, in accordance with Rule 10b5-1.
• The sales of common shares represent shares acquired following the exercise of stock options with a ten-year term expiring in less than one year in February 2026.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences for executives in publicly traded companies across all industries, including biotechnology. These plans allow insiders to sell shares at pre-determined times or prices to avoid accusations of trading on material non-public information, providing liquidity and diversification for executives.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for executive stock sales is a widely accepted and standard practice in corporate governance, aligning with best practices for managing insider transactions.
• The exercise of stock options nearing their expiration date is a common financial planning strategy for executives to realize value from their compensation packages, comparable to practices at other companies like Amgen or Gilead Sciences where executives frequently manage their equity awards.

Stakeholder Impact

• Shareholders: May view the executive's realization of value from options positively, reflecting past stock performance, but also as a routine diversification of holdings. No direct impact on company strategy or operations is implied.
• Employees, Customers, Suppliers, Creditors: No direct or indirect impact on these stakeholders is indicated by this type of insider transaction report.

Key Dates

Recommendation

The filing is a routine Form 4 detailing pre-planned insider transactions (option exercises and subsequent sales) under a Rule 10b5-1 plan. Such transactions are common for executives to manage personal finances and diversify holdings, and do not typically reflect a change in the company's fundamental outlook or performance. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Halozyme Therapeutics, HALO, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Executive Compensation, Helen Torley, Biotechnology, Pharmaceuticals